Fibronectin and immune complexes in rheumatic diseases

K E HERBERT,1 J S COPPOCK,1 A M GRIFFITHS,1 A WILLIAMS,2 M W ROBINSON,3 AND D L SCOTT1

From the Departments of 1Rheumatology and 2Chemical Pathology, St Bartholomew's Hospital and Medical College, West Smithfield, London; and the 3Department of Rheumatology, University of Birmingham, Birmingham

SUMMARY The relation between fibronectin and immune complexes in rheumatic diseases was examined in a series of linked studies. Fibronectin was present in immune complexes formed in vitro in the absence of Clq. Gel filtration chromatography showed complexed fibronectin was present in the serum of a patient with rheumatoid vasculitis, but not in normal serum; the complexed fibronectin coeluted with IgA and C3. Two dimensional immunoelectrophoresis showed a single fibronectin component was present in normal serum, but a number of components were present in serum from a rheumatoid patient. Polyacrylamide gel electrophoresis followed by immunoblotting for fibronectin showed that polyethylene glycol precipitates of synovial fluid contained immunoreactive components of a variety of sizes, indicating the presence of fragments of the molecule. An analysis of fibronectin in polyethylene glycol precipitates of paired serum and synovial fluid samples from 17 patients with rheumatoid arthritis and 16 with osteoarthritis showed more fibronectin was present in rheumatoid samples, especially in synovial fluid. More fibronectin was also present in synovial fluid than in serum polyethylene glycol precipitates; there was no direct relationship with Clq levels. All these results suggest that fibronectin is an integral component of immune complexes. This has potential pathogenic significance because it shows that a product of connective tissue cells may influence the functions of the immune system.

Immune complexes (IC) are involved in the pathogenesis of rheumatoid arthritis and other connective tissue diseases. Their persistence in pathological fluids is influenced by the efficiency of their phagocytosis by cells. Recent evidence has suggested that a connective tissue protein, fibronectin, may be associated with immunoglobulins and complement components in IC.1–4 Fibronectin is a high molecular weight glycoprotein (440 000–500 000) of plasma, tissue fluids, and tissues. It binds to macromolecules such as collagen, heparin, and fibrin,5–8 adheres to cells,9 and is a major opsonin of particulate material in plasma.10–12 This opsonic role could be important in facilitating removal of IC from tissue fluids.

Several studies have provided evidence that fibronectin is a potential constituent of immune complexes; it binds to Clq,13 to IgM rheumatoid factor,4 and to complexes formed experimentally by heating IgG2; and it is a component of serum polyethylene glycol (PEG) precipitates.1 These results may have other explanations unrelated to a role for fibronectin in IC formation. The presence of fibronectin in PEG precipitates could be explained by its cryoprecipitable properties14 15; by precipitation of large proteins by PEG and by adherence of fibronectin to denatured protein.

Because of these questions we have further studied in detail the relation between fibronectin and IC formation in rheumatic diseases. Our objectives were to define the relation between fibronectin and circulating IC, to evaluate the nature of complexed fibronectin, and to investigate the relation between fibronectin and Clq in IC.

Materials and methods

FORMATION OF IN VITRO IMMUNE COMPLEXES
IC were formed by mixing purified human IgM, C3,
(Sigma, Poole, Dorset, UK) at a final concentration of 20 μg/ml in phosphate buffered saline (PBS), pH 7.4, with goat antihuman IgM (Dakopatts, High Wycombe, UK) 1:40 in PBS (total volume 1 ml), in the presence or absence of fibronectin (0.33 mg/ml), for four hours at room temperature. These amounts of antigen and antibody were those required to reach the equivalence point as indicated by the manufacturer. Complexed proteins were precipitated by 2% (w/v) polyethylene glycol 6000 (PEG) (Sigma) at 4°C for three hours. We have shown previously that purified fibronectin is not precipitated by PEG (4% w/v). The resultant precipitate was washed once in 2% PEG and redissolved in PBS.

IC were also formed in the presence of normal human serum, which acted as a source of complement. Fibronectin was extracted from human serum by affinity chromatography (see below) to yield fibronectin depleted serum (containing 5% of the original fibronectin concentration measured by enzyme linked immunosorbent assay (ELISA)). This was diluted to give a final IgM concentration of 20 μg/ml and mixed with goat antihuman IgM antiserum and fibronectin as before.

**PURIFICATION OF FIBRONECTIN**

Fibronectin was purified by affinity chromatography on gelatin-Sepharose 4B using citrated normal human plasma.16

**TOTAL PROTEIN DETERMINATION**

The concentration of protein in PEG (2% w/v) precipitates was determined using the bicinchoninic acid procedure.17

**ELISA FOR FIBRONECTIN**

The assay was based on that of Selmer et al. 18 Plastic microtitre plate wells were coated (100 μl/well) with goat antihuman fibronectin (Sigma, Poole, Dorset, UK) (25 μg/ml in 0.05 M sodium carbonate buffer, pH 9-6) and incubated at room temperature for 17 hours. Each well was then washed twice with 100 μl PBS (0-01 M) containing Tween 20 (0-05% v/v) (PBS-Tween). Excess binding sites on the plate were blocked with PBS-Tween containing 1% bovine serum albumin (BSA) (100 μl) for one hour at room temperature. Standards and samples were added in PBS-Tween BSA (100 μl) and the plate incubated for one hour at room temperature. The standards used were in the range 1-6 to 205 μg/l of protein using fibronectin isolated from normal human plasma. Plates were washed three times with PBS-Tween and rabbit antihuman fibronectin (Dakopatts, Denmark) added (1:1000) in PBS-Tween-BSA (100 μl) before further incubation for one hour at room temperature. After washing, peroxidase conjugated goat antirabbit IgG (Sigma) was added (1:1000) in PBS-Tween-BSA (100 μl). After incubation for one hour at room temperature and after washing (×4), freshly prepared substrate solution (100 μl) was added to each well and the plate incubated at room temperature for 10 minutes (substrate solution: Na2HPO4.2H2O (0-1 M), citric acid (0-034 M) containing H2O2 (0-01%, w/v) (BDH, Poole, UK), and o-phenylenediamine (4-3 mM) (Sigma)). The reaction was terminated by adding 100 μl of sulphuric acid (2-5 M) and the absorbance at 492 nm read using a Uniscan plate reader (Flow Laboratories). Unknown values were calculated by reference to a semilogarithmic standard curve for purified fibronectin. The intra-assay coefficient of variation was 8%.

**ROCKET IMMUNOELECTROPHORESIS ASSAY FOR FIBRONECTIN**

This assay used a monospecific antiserum to fibronectin prepared by the immunodiagnostic research laboratory of the University of Birmingham. The assay has previously been described in detail.19

**COMPARISON OF ANALYTICAL METHODS FOR FIBRONECTIN DETERMINATION**

The amount of fibronectin in 45 whole sera and 42 PEG precipitates of sera was measured by both ELISA and rocket immunoelectrophoresis. The samples were from patients with either rheumatoid arthritis or systemic lupus erythematosus.

**GEL FILTRATION**

Elution profiles of serum fibronectin, complement component C3 (C3), and immunoglobulin A (IgA) were compared after gel filtration on Sephacryl S400 (Pharmacia, Uppsala, Sweden) of normal serum and serum from a rheumatoid arthritic patient with systemic vasculitis. Serum (1 ml) was applied to the column (50×1-5 cm) and proteins eluted with PBS, pH 7-4. The concentrations of fibronectin, C3, and IgA in the fractions were measured by single radial immunodiffusion using specific antisera and results expressed as relative concentrations for each protein.

**TWO DIMENSIONAL IMMUNOELECTROPHORESIS**

Two-dimensional immunoelectrophoresis was performed as described by Clarke and Freeman20 on serum and PEG precipitates of serum, using monospecific antiserum to fibronectin in the second dimension.
SOUDIUM DODECYL
SULPHATE-POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS-PAGE)
PEG (2% w/v) precipitates of serum and synovial fluid samples were prepared as described above (for
the formation of immune complexes in vitro). Precipitated proteins were separated by the SDS-
PAGE system of Laemmli21 in vertical slabs, using a 4–12% polyacrylamide gradient containing SDS
(0-1%) and a 5% polyacrylamide stacking gel. Typically electrophoresis was performed at a con-
stant current of 12-5 mA/gel for 17 hours with cooling to 10°C. Proteins were transferred to nitro-
cellulose paper (Bio-Rad, California, USA) using electrophoresis at 90 V for one hour at 5°C.
Imunochemical localisation of fibronectin was performed using rabbit antihuman fibronectin antiserum
(Dakopatts) and goat antirabbit peroxidase conjugated antiserum (Sigma), followed by colour
formation with diaminobenzidine and hydrogen peroxide as substrates for the peroxidase.

CLINICAL SPECIMENS
Paired samples of synovial fluid and serum were obtained from 17 patients with rheumatoid arthritis
and 16 with osteoarthritis. Serum was also obtained from six normal controls. The specimens were
centrifuged at 1000 g for 10 min and the supernatants removed and used immediately for studies
of IC. PEG precipitates were produced as described above. Fibronectin was measured by the ELISA
technique and Clq by single radial immunodiffusion using an assay kit supplied by Mercia Diagnostics.

Results

ASSOCIATION OF FIBRONECTIN WITH
IMMUNE COMPLEXES FORMED IN VITRO
The formation of IgM and anti-IgM IC was shown by measuring PEG precipitable protein (Table 1).

<table>
<thead>
<tr>
<th>Proteins added to fibronectin</th>
<th>Total protein in PEG precipitate (mg/ml)</th>
<th>Fibronectin in PEG precipitates µg/ml</th>
<th>% Control value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM alone</td>
<td>3-7 (1-7)</td>
<td>0-23 (0-06)</td>
<td>100 (26)</td>
</tr>
<tr>
<td>Anti-IgM and IgM</td>
<td>61-6 (11-7)*</td>
<td>1-48 (0-85)*</td>
<td>639 (368)</td>
</tr>
</tbody>
</table>

Values are mean (SD).
*Significantly higher by Mann-Whitney U test (p<0-01).

Table 2. Precipitation of fibronectin by PEG during in vitro complex formation in the presence of fibronectin depleted human serum (n=8)

<table>
<thead>
<tr>
<th>Proteins added to serum</th>
<th>Fibronectin in PEG precipitate µg/ml</th>
<th>% Control value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibronectin</td>
<td>0-07 (0-03)</td>
<td>100 (40)</td>
</tr>
<tr>
<td>Fibronectin and anti-IgM</td>
<td>0-43 (0-14)*</td>
<td>662 (220)</td>
</tr>
</tbody>
</table>

Values are mean (SD).
*Significantly higher by Mann-Whitney U test (p<0-01).

Analysis of the PEG precipitates by ELISA showed that the amount of precipitated fibronectin was signifi-
cantly increased when IC were produced (p<0-01 by Mann-Whitney U test). Exogenous fibronectin was a
constituent of PEG precipitable complexes formed by the addition of anti-IgM to fibronectin depleted
serum (Table 2). The amount of fibronectin precipitated was significantly greater when IC were formed
than in the control where antibody was omitted (Table 2). The relative amount of fibronectin precipitated
was similar when IC were synthesised using purified IgM or human serum.

GEL FILTRATION
Chromatography of normal serum showed IgA, C3, and fibronectin were only present in a single peak.
Serum from a patient with rheumatoid vasculitis showed a proportion of each of these proteins was present
in high molecular weight forms (Fig. 1). This suggests that IC were present in the serum and contained
IgA, C3, and fibronectin.

TWO DIMENSIONAL IMMUNOELECTROPHORESIS
Normal serum gave a single peak with antifibronectin in the second dimension (Fig. 2). Serum
from a rheumatoid patient showed a number of components were present, including a slow moving
immunoreactive fibronectin moiety.

SDS-PAGE AND IMMUNOBLOTTING
SDS-PAGE of PEG precipitates of serum and synovial fluid followed by immunoblotting with
antifibronectin antiserum was performed for patients with osteoarthritis (OA) and with rheumatoid
arthritis (RA). Examples are shown in Figs 3 and 4. Fibronectin was present mainly as a polypeptide of
molecular weight 220 000 in serum from a patient with OA (Fig. 3). There was evidence, however, of
lower molecular weight forms of fibronectin in synovial fluid from the same patient. In PEG-

Fibronectin and immune complexes in rheumatic diseases 737

C3 precipitates from RA synovial fluid than from OA synovial fluid (p<0.02 by Student's unpaired t test). The differences in serum were less pronounced (Table 3). The level of fibronectin in PEG precipitates of synovial fluid was greater than in serum for both groups of patients (p<0.01 by Student's paired t test). Conversely C1q concentrations in serum PEG precipitates were greater than those of synovial fluid. Therefore the ratio of serum/synovial fluid PEG precipitable fibronectin was low (less than 1) and for C1q was high (greater than 1).

precipitates of RA sera (Fig. 4) native fibronectin (molecular weight 220 000) and some smaller molecular weight polypeptides were observed. In contrast, a PEG precipitate of RA synovial fluid contained little native fibronectin, but many forms of lower molecular weight with immunoreactivity to antifibronectin antiserum were evident.

Fibronectin and C1q in RA and OA PEG precipitates
Significantly more fibronectin was present in PEG precipitates from RA synovial fluid than from OA synovial fluid (p<0.02 by Student's unpaired t test). The differences in serum were less pronounced (Table 3). The level of fibronectin in PEG precipitates of synovial fluid was greater than in serum for both groups of patients (p<0.01 by Student's paired t test). Conversely C1q concentrations in serum PEG precipitates were greater than those of synovial fluid. Therefore the ratio of serum/synovial fluid PEG precipitable fibronectin was low (less than 1) and for C1q was high (greater than 1).

Fibronectin and immune complexes in rheumatic diseases 737

precipitates of RA sera (Fig. 4) native fibronectin (molecular weight 220 000) and some smaller molecular weight polypeptides were observed. In contrast, a PEG precipitate of RA synovial fluid contained little native fibronectin, but many forms of lower molecular weight with immunoreactivity to antifibronectin antiserum were evident.

Fibronectin and immune complexes in rheumatic diseases 737

precipitates of RA sera (Fig. 4) native fibronectin (molecular weight 220 000) and some smaller molecular weight polypeptides were observed. In contrast, a PEG precipitate of RA synovial fluid contained little native fibronectin, but many forms of lower molecular weight with immunoreactivity to antifibronectin antiserum were evident.

Fibronectin and immune complexes in rheumatic diseases 737

precipitates of RA sera (Fig. 4) native fibronectin (molecular weight 220 000) and some smaller molecular weight polypeptides were observed. In contrast, a PEG precipitate of RA synovial fluid contained little native fibronectin, but many forms of lower molecular weight with immunoreactivity to antifibronectin antiserum were evident.
COMPARISON OF ELISA AND ROCKET TECHNIQUES
The presence of fibronectin fragments in some PEG precipitates raises a potential analytical problem: different antibodies may possess different specificities for fibronectin fragments. A second analytical difficulty is interference in the ELISA assay by rheumatoid factor. A comparison of ELISA and rocket assays using antisera to fibronectin from different sources showed these problems were not important. The two assays gave similar correlations with serum and with PEG precipitates: the Pearson correlation coefficients were r=0.69 (n=45) for serum and r=0.89 (n=42) for PEG precipitates. Overall their correlation was r=0.86 (n=87).

![Fig. 3 PAGE (4–12%) of 2% PEG precipitates of serum and synovial fluid, immunoblotted with antifibronectin antiserum. Paired serum (a) and synovial fluid (b) were prepared from a patient with osteoarthritis. MW=molecular weight in kilodaltons.](image)

![Fig. 4 PAGE (4–12%) of 2% PEG precipitates of serum and synovial fluid, immunoblotted with antifibronectin antiserum. (a) Serum from a patient with rheumatoid vasculitis; (b) and (c) serum and synovial fluid respectively taken from a patient with rheumatoid arthritis. MW=molecular weight in kilodaltons.](image)

Table 3 Comparison of fibronectin and C1q in serum and synovial fluid PEG precipitates in RA and OA

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Fibronectin (μg/ml)</th>
<th>C1q (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA serum</td>
<td>17</td>
<td>12 (16)</td>
<td>120 (59)</td>
</tr>
<tr>
<td>RA synovial fluid</td>
<td>17</td>
<td>234 (224)</td>
<td>68 (37)</td>
</tr>
<tr>
<td>RA serum/synovial fluid ratio</td>
<td>17</td>
<td>0.05</td>
<td>1.76</td>
</tr>
<tr>
<td>OA serum</td>
<td>16</td>
<td>7 (12)</td>
<td>73 (40)</td>
</tr>
<tr>
<td>OA synovial fluid</td>
<td>16</td>
<td>76 (111)</td>
<td>10 (12)</td>
</tr>
<tr>
<td>OA serum/synovial fluid ratio</td>
<td>16</td>
<td>0.09</td>
<td>7.30</td>
</tr>
</tbody>
</table>

Values are mean (SD).
Discussion

These results strongly suggest that fibronectin is a component of IC. The coelution of fibronectin with high molecular weight C3 and IgA in the rheumatoid vasculitic serum shows its presence in immune complexes is not merely an in vitro artefact produced by IC isolation by PEG. The amount of fibronectin in IC depends on their site of formation. Synovial fluid complexes contained more fibronectin than serum IC. This may be due to differences in the nature of the fibronectin molecule in synovial fluid. Although fibronectins are formed from a single gene, there are post-transcriptional differences in its polypeptide chain structure at different sites.\(^\text{22,23}\) Thus synovial fluid fibronectin is different from the serum form.\(^\text{24-27}\) Using SDS-PAGE with immunoblotting, however, we estimated the molecular weight of reduced serum and synovial fluid fibronectin each to be 220,000, which agrees with previous reports on plasma\(^8\) and cell surface fibronectins.\(^\text{28}\)

The immunoblotting studies show fibronectin in IC may be partially or completely degraded, most notably in synovial fluid complexes. Inflamed joints contain free proteolytic enzymes and macrophages and polymorphonuclear leucocytes capable of degrading fibronectin both enzymically and by a free radical mechanism. The propensity of fibronectin to damage by these mechanisms may be more marked in the synovial fluid form of the molecule. The altered pattern of immunoreactivity of serum fibronectin on two dimensional immunoelectrophoresis can be explained by both partial degradation and by complexing with other proteins. Such complexing could be similar to the IgA/\(\alpha_1\) antitrypsin complex seen in rheumatoid arthritic sera and synovial fluids.\(^\text{29,30}\) Enzymically formed fibronectin fragments possess altered biological activity compared with the active molecule.\(^\text{31,32}\) It has also been shown that some fragments may have specific effects not present in the intact molecule with a significant stimulating action on fibroblasts. The implication is that the binding of native or fragmented fibronectin to IC may influence their biological role or their removal from sites of immune related inflammation and tissue damage. Bykowska et al have shown that proteolysis of plasma fibronectin influences its apparent concentration in two immunoassays based on electroimmunoassay and immunoturbidimetric techniques.\(^\text{33}\) Our own results, however, suggest that in PEG precipitates the levels of fibronectin measured immunochemically are similar in two different assays—ELISA and rocket immunoelectrophoresis. This suggests that the levels of fibronectin in PEG precipitates found in our assay systems do not result from an artefact produced by partial degradation.

The in vitro formation of IC shows the relative amount of fibronectin precipitated by PEG is similar in the presence and absence of serum. Only trace amounts of serum proteins will have been added with the antiserum to IgM, including a very small quantity of complement proteins. These results therefore suggest that fibronectin can bind directly to IC and that this binding is not mediated by C1q. Conversely, it cannot be argued from our results that C1q binding does not account for a part of fibronectin adherence to IC; indeed there is considerable evidence supporting such a suggestion.\(^\text{3,13,34-36}\) Nevertheless, the analyses of paired serum and synovial fluid PEG precipitates provide further evidence that fibronectin adherence does not depend on the amount of C1q in IC. The relative amounts of fibronectin and C1q in IC are dependent upon the site at which IC are formed.

Although these results point to a role for fibronectin in IC formation, this will only be of biological significance if it can alter their handling in vivo. The demonstration of specific macrophage receptors for fibronectin\(^\text{37}\) suggested a potential role. The work of Saba and Jaffe showed that fibronectin is an opsonic protein,\(^\text{11}\) and more recent studies by Simpson and Boughton have shown its opsonic role is equal to that of IgG and complement in certain circumstances.\(^\text{12}\) Using the clearance of a charged colloid (dextran sulphate) as a model, Walton et al showed that high molecular weight dextran sulphate forms complexes containing fibronectin in rat plasma in vivo;\(^\text{38}\) its parenteral administration lowers plasma fibronectin acutely in a dose related fashion. The plasma changes are accompanied by deposition of dextran sulphate (shown histochemically as metachromatic material) and of fibronectin (shown by specific immunofluorescence) in an identical distribution within reticuloendothelial cells of rat liver and spleen. If one transposes IC for 'charged colloid' it is apparent that fibronectin has the potential to modify the clearance of IC and control some features of immunologically mediated disease. There is already evidence that fibronectin can bind to certain forms of IgG,\(^\text{39}\) to DNA,\(^\text{40}\) and possibly to C3.\(^\text{41}\) It also has a major role in binding to bacteria.\(^\text{42,43}\) It is thus probable that fibronectin is an important functional constituent of IC in rheumatic diseases. Our current results support this, though the exact pathogenic significance of the interaction of fibronectin with IC needs further definition.

We thank the Arthritis and Rheumatism Council, the Joint Research Board of the Medical College of St Bartholomew's Hospital, and the Peel Medical Foundation for their help and support.
References